Caladrius Biosciences, Inc. (CLBS): Eric Wei , director of Caladrius Biosciences, Inc. sold 87,500 shares on Jun 30, 2016. The Insider selling transaction was reported by the company on Jul 5, 2016 to the Securities and Exchange Commission. The shares were sold at $0.61 per share for a total value of $52,773.17 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 27, 2016, Eric Wei (director) sold 22,698 shares at $0.55 per share price.On Aug 18, 2015, David J Mazzo (CEO) purchased 20,000 shares at $1.40 per share price.Also, On Aug 13, 2015, Robert S Vaters (CFO) purchased 12,385 shares at $1.35 per share price.
Caladrius Biosciences Inc: On Friday, Jul 1, 2016 heightened volatility was witnessed in Caladrius Biosciences Inc which led to swings in the share price. The shares opened for trading at $0.61 and hit $0.65 on the upside , eventually ending the session at $0.63, with a gain of 6.78% or 0.04 points. The heightened volatility saw the trading volume jump to 2,41,739 shares. The 52-week high of the share price is $2.0302 and the company has a market cap of $37 M . The 52-week low of the share price is at $0.401.
Company has been under the radar of several Street Analysts.Caladrius Biosciences Inc is Upgraded by H.C. Wainwright to Buy and the brokerage firm has set the Price Target at $1.25. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Apr 29, 2016.
Caladrius Biosciences Inc. formerly NeoStem Inc. is a clinical-stage biopharmaceutical company. The Company’s clinical program is based on its dendritic cell and cancer cell technology. It is focused on the development of a cancer treatment designed to focus the cells responsible for tumor growth and metastasis known as cancer or tumor initiating cells (CSCs). Its lead product candidate based on this platform technology is NBS20 (targeted cancer immunotherapy) which is in Phase II trials focuses on malignant melanoma as an initial indication. Its therapeutic platforms also include ischemic repair (CD34 Cell Program) and immune modulation (T Regulatory Cell Program). Its CD34 Cell Program develops therapies designed to address diseases and conditions caused by ischemia. Its product candidate in CD34 Cell Program is NBS10 which has completed Phase I clinical trials. Under T Regulatory Cell Program the Company is developing NBS03D which is in the Phase I clinical trial stage.